文献速递细胞病理与分子病理消化与肝胆胰病理胸部病理

泛癌种分子生物标志物:外科病理医生的实践考量

Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist.
PubMed 文献 · Mod Pathol · 2025-03-07

本文综述了随着二代测序技术发展而涌现的泛癌种分子生物标志物,包括已获FDA批准的肿瘤不可知疗法相关标志物(如MSI-H/dMMTMB、NTRK融合、BRAF V600E)及在研标志物(如FGFR/RET/ROS1融合、ERBB2扩增等),并探讨了外科病理与分子病理交汇处的概念与技术考量,旨在为病理医生将分子检测纳入常规肿瘤评估提供实践指导。

要点

  • FDA已批准多个泛癌种标志物对应疗法:MSI-H/dMMTMB用帕博利珠单抗,NTRK融合用拉罗替尼/恩曲替尼,BRAF V600E用达拉非尼联合曲美替尼。
  • 在研泛癌标志物包括FGFR、RET、ROS1融合,ERBB2扩增,以及AKT1/2/3、NF1、RAS/MAPK通路突变。
  • 外科病理医生需理解分子检测的概念与技术考量,以将泛癌标志物检测合理整合至常规肿瘤评估流程。

核心结论

  • 泛癌种分子标志物正快速从研究走向临床,病理医生需在常规工作中整合分子检测思维。

研究设计与样本

  • 综述:首先探讨外科病理与分子病理交叉处的概念和技术考量,随后概述已确立和新兴的泛癌种分子标志物及其诊断与临床应用。

主要发现

  • FDA批准的肿瘤不可知疗法对应标志物包括MSI-H/dMMTMB(帕博利珠单抗)、NTRK融合(拉罗替尼、恩曲替尼)和BRAF V600E(达拉非尼联合曲美替尼)。
  • 在研泛癌标志物包括FGFR、RET、ROS1融合,ERBB2扩增,以及AKT1/2/3、NF1、RAS通路和MAPK通路突变。

临床怎么用

  • 病理医生应在常规肿瘤评估中考虑泛癌种分子标志物检测,以指导肿瘤不可知疗法的患者筛选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traditional anatomic pathologic classification of cancer is based on tissue of origin and morphologic and immunohistochemical characterization of the malignant cells. With the technological improvements of massively parallel or next-generation sequencing, oncogenic drivers that are shared across different tumor types are increasingly being identified and used as pan-cancer biomarkers. This approach is reflected in the growing list of Food and Drug Administration-approved tumor-agnostic therapies, including pembrolizumab in the setting of microsatellite instability and high tumor mutational burden, larotrectinib and entrectinib for solid tumors with NTRK fusions, and combined dabrafenib-trametinib for BRAF V600E-mutated neoplasms. Several other biomarkers are currently under investigation, including FGFR, RET, and ROS1 fusions; ERBB2 amplification; and mutations in the AKT1/2/3, NF1, RAS pathway and MAPK pathway. As molecular assays are increasingly incorporated into routine tumor workup, the emergence of additional pan-cancer biomarkers is likely to be a matter more of "when" than "if." In this review, we first explore some of the conceptual and technical considerations at the intersection of surgical and molecular pathology, followed by a brief overview of both established and emerging molecular pan-cancer biomarkers and their diagnostic and clinical applications.

来源:Mod Pathol,查看原文。版权归原作者所有。

引用

  1. Jafari P, Forrest ME, Segal J, et al. Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist. Mod Pathol. 2025. PMID: 40058460. doi:10.1016/j.modpat.2025.100752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。